- This topic has 1 reply, 2 voices, and was last updated 3 years, 5 months ago by
.
-
Posts
-
The time period of 2005-2010 was the inception of the CBD industry, as it is known today. This period of time in CBD research was when researchers began to become more enlightened as to the potential of CBD, THC and of other cannabinoids. The CBD industry was still mostly known and studied in terms of medical cannabis, until the next decade. But entrepreneurs and cannabis scholars worked harder at lending a scientific perspective to this rising interest in CBD and other cannabinoids. The reward and result were that more was learned about CBD between 2005 and 2010 than in any previous five year time period.
Augmenting prior research, there was a review in 2006 of available evidence that was sought out to more fully discern the antipsychotic and anti- schizophrenia potential of CBD. Cannabidiol appears to lessen the action of THC to induce psychosis. This effect was seen both in animal studies, and in clinical studies involving psychosis induced by ketamine.
Case studies of schizophrenic patients were conducted in which the patients were given CBD. In addition, a preliminary study of a controlled trial comparing CBD with an atypical antipsychotic medication, have shown that CBD can be a safe and well tolerated treatment for schizophrenia. Future studies on the use of CBD in other psychotic conditions, in addition to schizophrenia, in which CBD is used comparatively with traditional, atypical antipsychotic medication, are indicated.
- You must be logged in to reply to this topic.